Check Your Claims Before Reviewers Do

 Quick Explanation Copied

 Long Explanation

Scientific Strength of Weston B. Struwe

Struwe operates at the intersection of glycomics, native mass spectrometry (MS), and mass photometry, with a coherent research identity: pushing structural-biology measurements toward native, real-time, single-molecule and single-tissue-section regimes. OpenAlex records ~188 works, ~7,310 citations, and an h-index of 48 with peak annual citation counts of ~1,371 (2016) and ~1,401 (2018), driven partly by methodological landmarks such as the Science mass-photometry paper (758 citations) and a Nature paper on interfacial lipids (402 citations) Quantitative mass photometry, Science 2018. Note a discrepancy: a secondary record lists h-index 8 / 236 citations across 38 papers—almost certainly a scoped or partial subset—so the OpenAlex profile is the better global estimate.

Recent first/corresponding-author preprints show high methodological novelty. Iterative bump-and-hole engineering of MGAT1 achieved cellularly selective bioorthogonal tagging with an optimized UDP-GlcNAc analog, integrating enzymology, MD/VAMPnets modeling, and glycoproteomics MGAT1 bump-and-hole reporter preprint. The LemonCatcher SelQueX study engineered an acidophilic Tag/Catcher enabling targeted in-cell HDX-MS (>60% capture at pH 2.5; >90% purification in 10 min; n=3 biological replicates) SelQueX in-cell HDX-MS method. Continuous mass photometry by single-molecule trapping achieved hour-long, ~1 kDa-precision trajectories on spike-ligand binding Continuous single-molecule mass photometry. The human-brain native-MS study is scientifically ambitious—mapping endogenous mGluR2/3 heterodimers regionally (mouse cortex ~22%, hippocampus ~11%; human OFC ~70%, sgACC ~50%; DEPR OFC ~80% vs CON ~59%)—but rests on small postmortem cohorts (DEPR n=7, CON n=8, sgACC n=4) with medication/PMI confounds and cross-sectional design precluding causal inference Native MS of human brain receptor assemblies. The Ebola GP study is mechanistically rich (Sudan GPcl KD 0.42 µM vs Mayinga 2.3 µM) but limited to recombinant ectodomains, pre-fusion-stabilized constructs, and no live-virus assays Ebola GP allosteric remodelling across species.

Strengths: consistent high-novelty method creation; deployment in top venues; strong collaborative network (Robinson, Benesch, Kukura, Bertozzi, Crick/Oxford); transparent limitation reporting in most works; data deposits via ProteomeXchange for several studies. Weaknesses/blindspots: repeated small sample sizes in human cohorts (n=4–8 per group); self-assessed reproducibility scores of 5–7 on recent work; extensive Refeyn Ltd. shareholdings/advisory roles create potential incentive bias around mass photometry claims (disclosed, but requiring independent replication); one pilot depression EV study (n=23) was explicitly feasibility-only with low generality TRD serum/EV proteomics pilot. Verdict (confidence: moderate-high): a technically exceptional, inventive structural-MS scientist whose weakest link is translational human biology, not chemistry or instrumentation. Larger, independently replicated human cohorts and full raw-data/code release would most strengthen his record.

 BGPT Author Review

Scientific Quality

h-index 48 with 7,310 citations reflects real field impact anchored by a Science and a Nature paper. Method-invention record (mass photometry applications, SelQueX, bump-and-hole reporters) is genuinely strong. Deductions: limited independent replication of recent preprints, small human cohorts, and industry entanglements (Refeyn shareholdership) that could bias validation standards.

Communication Quality

Papers report quantitative results and limitations transparently, though recent preprints contain internally conflicting kinetic values (noted in the MGAT1 extraction) and some data/code availability is on-request only, which impedes clarity and reuse.

Author Novelty

Consistently creates new methods rather than applying existing ones: acidophilic Tag/Catcher HDX-MS, continuous trapped mass photometry, bioorthogonal glycosyltransferase reporters, native MS from single brain sections.

Scientific Rigor

Strong quantitative instrumentation work with proper controls in vitro, but recurring weaknesses: small human cohorts (n=4–8/group), cross-sectional designs, ~15% systematic mass offsets, missing deposited raw data in some studies, and nominal p<0.05 in the EV pilot.